The New Biology of Pheochromocytomas

Saturday, May 14, 2022

9:00 AM – 10:00 AM

Location: Main Stage - Sapphire IJMN (Level 4)

Speaker(s)

Karel Pacak, MD, PhD, DSc, FACE
NIH
Bethesda, Maryland, United States

Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

PDF Slides

Moderator(s)

Oksana Hamidi, DO
Endocrinologist
UT Southwestern Medical Center
Dallas, Texas, United States

Disclosure: Corcept Therapeutics Inc (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- March 2020); Novo Nordisk (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- October 2020); Stongbridge Pharma (Self) : Consulting Fees (e.g., advisory boards) (Status: Terminated --- Nov 2020)

Learning Objectives:

Outline the newest clinical and basic discoveries related to hereditary pheochromocytoma and paraganglioma
Learn about new approaches for biochemical diagnosis of pheochromocytoma and paraganglioma including metabolomics
Outline the newest discoveries regarding functional imaging of pheochromocytoma and paraganglioma, including newest imaging guidelines and treatment options related to metastatic tumors focusing on personalized medicine

Participants should be aware of the following financial/non-financial relationships:

Karel Pacak, MD, PhD, DSc, FACE: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Oksana Hamidi, DO: Corcept Therapeutics Inc (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards); Novo Nordisk (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards); Stongbridge Pharma (Individual(s) Involved: Self): Consulting Fees (e.g., advisory boards)